Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Assets (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Assets for 10 consecutive years, with $53.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets fell 48.47% to $53.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $53.7 million, a 48.47% decrease, with the full-year FY2024 number at $62.2 million, down 41.33% from a year prior.
  • Assets was $53.7 million for Q3 2025 at Rein Therapeutics, down from $57.5 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $109.4 million in Q2 2024 to a low of $12.8 million in Q3 2023.
  • A 5-year average of $55.0 million and a median of $54.8 million in 2021 define the central range for Assets.
  • Peak YoY movement for Assets: plummeted 58.57% in 2023, then surged 712.8% in 2024.
  • Rein Therapeutics' Assets stood at $48.5 million in 2021, then crashed by 54.61% to $22.0 million in 2022, then soared by 381.7% to $106.0 million in 2023, then tumbled by 41.33% to $62.2 million in 2024, then fell by 13.64% to $53.7 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Assets are $53.7 million (Q3 2025), $57.5 million (Q2 2025), and $57.6 million (Q1 2025).